CRDF.US Cardiff Oncology Inc

Healthcare Biotechnology USA Stocks
0.7261 USD
Close of Nov 14, 2026
0.7100 3.31
Market cap
USD 56.5M
P/E
-
P/B
2.13x
ROE
-144.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CRDF.US undervalued?

Graham number

The Graham number of Cardiff Oncology Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Cardiff Oncology Inc fundamental analysis

No fundamental analysis for Cardiff Oncology Inc yet.

Cardiff Oncology Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Cardiff Oncology Inc

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic…

Full company profile